Stryker Pediatric Mandibular Distractor 2
Device Facts
| Record ID | K181504 |
|---|---|
| Device Name | Stryker Pediatric Mandibular Distractor 2 |
| Applicant | Stryker |
| Product Code | MQN · Dental |
| Decision Date | Sep 11, 2018 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 872.4760 |
| Device Class | Class 2 |
| Attributes | Therapeutic, Pediatric |
Indications for Use
The Stryker Pediatric Mandibular Distractor 2 is intended to be used for bone stabilization and lengthening of the mandibular body and ramus.
Device Story
Stryker Pediatric Mandibular Distractor 2 (PMD 2) is a temporary implant system for mandibular distraction osteogenesis. System components include a distractor body with integrated footplates, a sliding footplate, an activation joint, and an integrated anti-reverse feature. The device is surgically fixated to the mandibular body or ramus using screws. During operation, a removable activation rod is attached to the distractor; an external activation handle/key is used to initiate bone segment distraction. The anti-reverse feature prevents unintended movement of the sliding footplate and is deactivated using a specific instrument. The device is provided sterile. It is intended for use by surgeons in a clinical setting to treat congenital or post-traumatic mandibular defects in pediatric patients. The device allows for controlled, gradual bone lengthening, potentially improving functional and aesthetic outcomes for the patient.
Clinical Evidence
No clinical data. Substantial equivalence is supported by non-clinical bench testing, including biocompatibility (ISO 10993-5, -12, -18), corrosion resistance, dynamic compression-tensile force, distraction force, anti-reverse mechanism functionality, torque to failure, blood influence, end-user validation, shelf-life aging, and gamma sterilization validation (ISO 11137, ISO 11737).
Technological Characteristics
Materials: Commercially pure titanium (ASTM F67), stainless steel, nickel cobalt alloy, aluminum oxide. Principle: Mandibular distraction osteogenesis via screw fixation. Dimensions: 20/30 mm distraction lengths; 4.3 mm height profile; 1.7/1.9 mm screw diameters. Connectivity: None. Sterilization: Gamma radiation (25 kGy, SAL 10^-6).
Indications for Use
Indicated for bone stabilization and lengthening of the mandibular body and ramus to correct congenital or post-traumatic defects in neonates and children up to 4 years old.
Regulatory Classification
Identification
A bone plate is a metal device intended to stabilize fractured bone structures in the oral cavity. The bone segments are attached to the plate with screws to prevent movement of the segments.
Predicate Devices
- Stryker Pediatric Mandible Distractor (K133398)
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
September 11, 2018
Stryker Gregory Gohl Sr. Regulatory Affairs Specialist 750 Trade Centre Way - Suite 200 Portage, Michigan 49002
Re: K181504
Trade/Device Name: Stryker Pediatric Mandibular Distractor 2 Regulation Number: 21 CFR 872.4760 Regulation Name: Bone Plate Regulatory Class: Class II Product Code: MON Dated: August 9, 2018 Received: August 13, 2018
Dear Gregory Gohl:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
{1}------------------------------------------------
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Mary S. Runner -S
For Tina Kiang, Ph.D. Acting Director Division of Anesthesiology. General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
510(k) Number (if known)
### K181504
Device Name Stryker Pediatric Mandibular Distractor 2
### Indications for Use (Describe)
The Stryker Pediatric Mandibular Distractor 2 is intended to be used for bone stabilization and lengthening of the mandibular body and ramus. The Stryker Pediatric Mandibular Distractor 2 is indicated to correct congenital or post traumatic defects in the body and ramus of the mandible of neonates and children up to 4 years old.
| Type of Use (Select one or both, as applicable) |
|-------------------------------------------------|
|-------------------------------------------------|
2 Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
### CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the word "stryker" in a bold, sans-serif font. The letters are all lowercase, and the word is slightly angled upwards from left to right. A small registered trademark symbol is located to the upper right of the letter 'r'.
# Section 5. 510(k) Summary
This section provides a summary of 510(k) information in accordance with the requirements of 21 CFR 807.92.
- SUBMITTER [§807.92(a)(1)] I.
| 510(k) Owner: | Stryker Leibinger GmbH & Co. KG<br>Boetzinger Strasse 41<br>79111 Freiburg, Germany |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Submitter/ Contact<br>Person: | Gregory Gohl<br>Sr. Regulatory Affairs Specialist<br>Stryker Craniomaxillofacial<br>750 Trade Centre Way<br>Portage, MI 49002<br>Phone: 269-389-4319<br>Fax: 877-648-7114 |
Date Prepared: August 9, 2018
#### II. DEVICE [§807.92(a)(2)]
| Trade/Device Name: | Stryker Pediatric Mandibular Distractor 2 |
|-----------------------------------------------------|-----------------------------------------------|
| Abbreviated Name: | PMD 2 |
| Classification Name: | "Bone plate" per 21 CFR 872.4760 |
| Common or Usual<br>Name: | External Mandibular Fixator and/or Distractor |
| Regulatory Class: | Class II |
| Product Code: | MQN |
| Regulation Medical<br>Specialty and<br>Review Panel | Dental |
{4}------------------------------------------------
#### PREDICATE DEVICE [§807.92(a)(3)] III.
Stryker Pediatric Mandible Distractor - K133398
#### IV. DEVICE DESCRIPTION [§807.92(a)(4)]
The Stryker Pediatric Mandibular Distractor 2 (PMD 2) system is a distraction system consisting of the following major components: distractor with integrated footplates, integrated anti-reverse feature, removable activation rod, deactivation instrument, and a small activation handle/activation key. The distractor initially stabilizes and then gradually distracts the bone segments separated by osteotomy. The removable activation rod is connected to the distractor and provides the point of attachment for the external small activation handle/activation key used to initiate the distraction of the bone segments. The anti-reverse feature is deactivated with the corresponding deactivation instrument.
The Stryker Pediatric Mandibular Distractor 2 (subject device) includes the distractor body. integrated footplates, a sliding footplate, integrated anti-reverse feature, and the activation joint (to attach the activation rod). It is available in eight variants with two different distraction lengths (20 and 30 mm) and right or left footplate configuration with footplate sizes having either a 2X2 or 3X3 hole pattern.
#### V. INDICATIONS FOR USE [§807.92(a)(5 )]
| | Subject Device | Predicate Device - K133398 |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications for<br>Use | The Stryker Pediatric Mandibular<br>Distractor 2 is intended to be used<br>for bone stabilization and<br>lengthening of the mandibular<br>body and ramus. The Stryker<br>Pediatric Mandibular Distractor 2<br>is indicated to correct congenital<br>or post traumatic defects in the<br>body and ramus of the mandible<br>of neonates and children up to 4<br>years old. | The Stryker Pediatric Mandible<br>Distractor is intended to be used<br>for bone stabilization and<br>lengthening of the mandibular<br>body and ramus. The Stryker<br>Pediatric Mandible Distractor is<br>indicated to correct congenital or<br>post traumatic defects in the body<br>and ramus of the mandible of<br>neonates and children up to 4 years<br>old. |
### TABLE 5-1: COMPARISON OF INDICATIONS FOR USE
{5}------------------------------------------------
The subject device is indicated for use in the same anatomic areas as the predicate device and for the same surgical applications. There is no difference in the Indications for Use.
### A. Intended Use
The Stryker Pediatric Mandibular Distractor 2 is intended to be used for bone stabilization and lengthening of the mandibular body and ramus.
#### COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE VI. PREDICATE DEVICE [§807.92(a)(6)]
The Stryker Pediatric Mandibular Distractor 2 is compared to its predicate device for substantial equivalence based on the following criteria:
- A. Principle of Operation
- B. Technological and Operational Characteristics
### A. Principle of Operation
The basic operational principle of the subject device, as well as, the predicate device is for bone stabilization and lengthening. The method of site preparation and fixation is the same for both the subject and predicate device. The subject device and predicate device are temporary implants.
### B. Technological and Operational Characteristics
The Stryker Pediatric Mandibular Distractor 2 (PMD 2) is the second generation of the Stryker Pediatric Mandible Distractor (PMD) currently in the market. Hence, the PMD 2 is similar to its predicate device, PMD, having the following technological and operational characteristics:
- Material: Both the subject device and predicate device are made of biocompatible titanium according to standards.
- The subject device is made of commercially pure titanium (CP Ti), stainless O steel, nickel cobalt alloy, and aluminum oxide.
- The predicate device is made of commercially pure titanium (CP Ti) and o stainless steel
- Mode of Fixation: Implant fixation with screws is the same as the predicate device. -
- Design: The design of the subject device is similar to the predicate device. They both have the same components: body, footplates, activation joint (for activation rod connection). In addition, the subject device uses the same components and interfaces (e.g. activation rod) for distraction activation as the predicate device. The
{6}------------------------------------------------
subject device and its predicate device offer various options of distraction lengths and footplate sizes. The footplates of the subject device and predicate device are fully integrated (i.e., non-welded). The subject device contains an integrated antireverse feature that uses a deactivation instrument to be deactivated compared to the predicate device, which does not.
- Packaging: The subject device is sterile, and the predicate device is dispensed nonsterile.
The table below compares the technological characteristics of the PMD 2 to the predicate device (Table 5-2).
{7}------------------------------------------------
| Feature | Subject Device | Predicate Device | Explanation of<br>Differences |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| Principles of<br>Operation | Mandibular Distraction Osteogenesis | Mandibular Distraction Osteogenesis | Identical |
| Mechanism of<br>Action | The PMD 2 devices are fixated to the body or ramus of the<br>mandible for mandibular lengthening or advancement | The PMD devices are fixated to the body or ramus of the<br>mandible for mandibular lengthening or advancement | Identical |
| Mode of<br>Fixation | Implant fixation with screws | Implant fixation with screws | Identical |
| Exemplary<br>illustration of<br>device | Image: Stryker CE 62-02330 | Image: Stryker CE 62-01330 | Identical except for<br>the integrated anti-<br>reverse feature |
| Design | Components: Body, Integrated Footplates, Activation Joint, Integrated Anti-Reverse Feature Distraction Lengths Options: 20 & 30 mm Footplate Size Options: 2x2 & 3x3 Low Height Profile: 4.3 mm Screw Diameter: 1.7 & 1.9 mm Advancement: 1 turn = 0.5 mm | Components: Body, Integrated Footplates, Activation Joint Distraction Lengths Options: 20 & 30 mm Footplate Size Options: 2x2 & 3x3 Low Height Profile: 4.3 mm Screw Diameter: 1.7 & 1.9 mm Advancement: 1 turn = 0.5 mm | Identical except for<br>the integrated anti-<br>reverse feature |
| Material | Titanium (Commercially Pure Titanium acc. ASTM F67)<br>Stainless Steel<br>Nickel Cobalt Alloy<br>Aluminum Oxide | Titanium (Commercially Pure Titanium acc. ASTM F67)<br>Stainless Steel | Similar. The<br>additional materials<br>are due to the anti-<br>reverse feature |
| Packaging | Sterile | Non-sterile | Different due to the<br>need to fulfill sterile<br>product European<br>market requirements |
### TABLE 5-2 – TECHNOLOGICAL CHARACTERISTICS COMPARISON MATRIX OF SUBJECT PMD 2 TO THE PREDICATE
Overall, any changes do not alter the subject device significantly, and do not represent a new worst case in design.
{8}------------------------------------------------
# VII. PERFORMANCE DATA [§807.92(b)(1)]
The Stryker Pediatric Mandibular Distractor 2 was subjected to non-clinical testing including verification and validation testing of biocompatibility, manufacturing cleaning, gamma sterilization, corrosion resistance, dynamic compression-tensile force, distraction force, antireverse feature functionality and torque to failure, blood influence, design validation - end user test, and shelf life (aging and packaging). The system passed all tests.
Specifically, the following performance data were provided in support of the substantial equivalence determination.
## Biocompatibility Testing
The biocompatibility evaluation for the PMD 2 system was conducted in accordance with the FDA Guidance "Use of International Standard ISO 10993-1, 'Biological evaluation of medical devices - Part 1 Evaluation and testing within a risk management process"", issued June 16, 2016, and International Standard ISO 10993-1 "Biological Evaluation of Medical Devices -Part 1: Evaluation and Testing Within a Risk Management Process," as recognized by the FDA. The tests supported the biocompatibility of the device.
The implant is mainly made from commercially pure titanium (CP Ti), which conforms to ASTM F67 for chemical composition, the same as the predicate device. Cytotoxicity testing was performed using DIN EN 10993-5:2009, Biological evaluation of medical devices Part 5: Tests for in vitro cytotoxicity. Corrosion testing was performed using internal instruction DQI 30-022, Implant Corrosion Testing, Stryker Trauma & Extremities, 2017. The tests supported the biocompatibility of the device.
{9}------------------------------------------------
# Performance Bench Testing
The following performance bench tests were completed:
| Characteristic | Tests | Test Methods | Results |
|------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| Biocompatibility | Cytotoxicity | Verify biocompatibility in regards to<br>cytotoxicity through in vitro indirect<br>extract tests per ISO-10993-5 and ISO<br>10993-12 | Acceptance<br>criterion were<br>met; tests were<br>passed. |
| | GC/MS<br>Fingerprint | Verify biocompatibility in regards to<br>GC/Fingerprint through in vitro<br>indirect extract tests per ISO-10993-18<br>and ISO 10993-12 | Acceptance<br>criterion were<br>met; tests were<br>passed. |
| | Corrosion | Verify corrosion behavior of implant<br>and instruments | Corrosion<br>resistance was<br>proven; tests<br>were passed. |
| Performance | Dynamic<br>Compression<br>and Tensile<br>Force | Verify that unintended movement of<br>the sliding footplate is properly<br>prevented with an activated "anti-<br>reverse" mechanism. | Acceptance<br>criterion were<br>met; tests were<br>passed. |
| | Distraction<br>Force | Verify the distraction force and the<br>ability of small activation handle to<br>transmit sufficient torque. | Acceptance<br>criterion were<br>met; tests were<br>passed. |
| | Anti-Reverse<br>Mechanism<br>Functionality | Verify that activation and<br>deactivation of the anti-reverse<br>feature is possible within shelf life. | Acceptance<br>criterion were<br>met; tests were<br>passed. |
| | Torque to<br>Failure of<br>Anti-Reverse<br>Mechanism | Verify that the torque to failure is<br>high enough that the resistance caused<br>by turning against the activated anti-<br>reverse mechanism is recognizable by<br>the user before breakage. | Acceptance<br>criterion were<br>met; tests were<br>passed. |
| | Deactivation<br>Instrument<br>Lifetime<br>Usage | Verify that deactivation of "anti-<br>reverse" feature is always possible<br>with the deactivation instrument<br>within its lifetime usage. | Acceptance<br>criterion were<br>met; tests were<br>passed. |
| Characteristic | Tests | Test Methods | Results |
| | Effect of<br>Blood<br>Contact on<br>Anti-Reverse<br>Mechanism<br>Functionality | Verify that the functionality of the<br>anti-reverse feature is given after<br>contact with blood | Acceptance<br>criterion were<br>met; tests were<br>passed. |
| | End User<br>Validation | Validate that the end user needs of the<br>PMD 2 system are fulfilled | Acceptance<br>criterion were<br>met; tests were<br>passed |
| Shelf Life | Aging | Verify that the device, including the<br>anti-reverse feature, maintains<br>properties and characteristics within<br>shelf life. | Acceptance<br>criterion were<br>met; tests were<br>passed. |
| | Sterile<br>Packaging | Simulation of handling and<br>transportation from Stryker's stock to<br>end customer and investigation of the<br>integrity of the packaging system,<br>following ISO 11607-1 and ASTM<br>D4169 | Acceptance<br>criterion were<br>met; tests were<br>passed. |
| Sterilization | Gamma<br>Sterilization<br>Validation | VDmax25 Method for substantiation of<br>25 kGy as sterilization dose according<br>to ISO 11137-1, -2 and -3 for multiple<br>production batches for verifying<br>compliance with EN 556 to achieve a<br>SAL 10-6.<br><br>Microbiological Testing Methods to<br>verify the suitability of of the<br>microbiological test methods used for<br>the bioburden determination and<br>sterility testing for the subsequently<br>planned verification experiment to<br>validate gamma sterilization in<br>accordance to ISO 11737-1 and -2. | Method<br>Validated |
{10}------------------------------------------------
Image /page/10/Picture/0 description: The image shows the word "stryker" in a bold, sans-serif font. The word is all lowercase except for the first letter, which is uppercase. To the right of the word is the registered trademark symbol, a capital R inside a circle. The logo is simple and modern.
Overall, the results of the performance bench tests support the substantial equivalence of the subject device.
{11}------------------------------------------------
### Animal Testing
Animal testing was not required as a basis for substantial equivalence.
## Clinical Testing [§807.92(b)(2)]
Clinical testing was not required as a basis for substantial equivalence.
## VIII. CONCLUSIONS [§807.92(b)(3)]
The Stryker Pediatric Mandibular Distractor 2 is substantially equivalent to its predicate device with respect to its intended use, design, materials, and operational principle. The results of the non-clinical data demonstrate the Stryker Pediatric Mandibular Distractor 2 will perform as intended in the specified use conditions. Further, the performance testing confirms that the Stryker Pediatric Mandibular Distractor 2 is safe and effective for its intended use, and it performs as well as the predicate device. According to the comparison based on the requirements of 21 CFR 807.92 and the information provided herein, it is concluded that the information included in this submission supports substantial equivalence.
